Alnylam Pharmaceuticals, Inc. $ALNY Stock Holdings Boosted by Hsbc Holdings PLC

Hsbc Holdings PLC grew its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 22.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 89,517 shares of the biopharmaceutical company’s stock after purchasing an additional 16,503 shares during the quarter. Hsbc Holdings PLC’s holdings in Alnylam Pharmaceuticals were worth $35,675,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. MV Capital Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $25,000. HM Payson & Co. acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth about $27,000. Golden State Wealth Management LLC raised its position in Alnylam Pharmaceuticals by 100.0% in the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 36 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Alnylam Pharmaceuticals in the third quarter worth about $29,000. Finally, Ameriflex Group Inc. acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at about $32,000. Institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ALNY. Jefferies Financial Group restated a “hold” rating and set a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Truist Financial cut their target price on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a research note on Monday, April 13th. Wells Fargo & Company lifted their price target on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research report on Friday, May 1st. HC Wainwright reaffirmed a “buy” rating and issued a $510.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, June 4th. Finally, Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $463.13.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $288.18 on Wednesday. Alnylam Pharmaceuticals, Inc. has a one year low of $273.11 and a one year high of $495.55. The company has a 50-day moving average of $298.80 and a two-hundred day moving average of $334.73. The stock has a market cap of $38.47 billion, a price-to-earnings ratio of 78.74 and a beta of 0.29. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm’s revenue was up 96.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.44) earnings per share. On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the business’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the sale, the insider directly owned 9,443 shares in the company, valued at approximately $3,120,156.06. This trade represents a 19.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 7,740 shares of company stock worth $2,420,214. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.